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INTRODUCTION
Moyamoya disease is a rare progressive cerebrovascular disease characterized by 
bilateral stenosis of vasculature of the Circle of Willis, specifically the distal internal 
carotid arteries, that leads to extensive collateral circulation. These dilated collateral 
vessels are described as having a hazy “puff of smoke” appearance on angiography. 
“Moyamoya” is the Japanese word for this characteristic appearance. The disease was 
originally described in Japan in 1957 1 and introduced to the English literature in 1969.2 
The disease is most known for its distribution in Asian populations, but recently there has 
been more research and attention given to moyamoya in Europe and North American 
Moyamoya disease presents clinically due to the ischemic and hemorrhagic complica-
tions of abnormal cerebral vascularity.3,4
Epidemiology
Moyamoya disease was originally described in Japanese populations but is present in a 
variety of ethnicities.3,5,6 In Japan, the incidence per 100,000 patient years is between 
0.35 to 0.943 with a male: female ratio of 1:1.87. In the US, incidence ranged from 0.05 
to 0.17 per 100,000 patient years with a similar gender distribution.3,6 Other population 
studies have not been as robust but European studies show moyamoya statistics that 
are more similar to American findings than those of Asian moyamoya findings.4 There is 
a bimodal distribution of incidence: in early childhood and adulthood, but the double-
peaked incidence is less dramatic in the US and Europe.4,8 Children typically present with 
the ischemic symptoms and adults can present with either ischemic or hemorrhagic 
type, with the ischemic type predominating.5,9 Overall, the hemorrhagic type is more 
common in Asia than the U.S.9 The incidence has been increasing with time, which may 
be due to increased awareness.5
Etiology
The etiology of moyamoya disease is largely unknown. However, there are genetic 
susceptibilities and biochemical correlates that warrant further research. This impor-
tance is highlighted in the 10-15% of moyamoya disease cases that are familial.10 The 
proposed mechanism of inheritance is autosomal dominant with incomplete penetrance 
but it is likely there are polygenic interactions as well.11 Currently, screening is not recom-
mended for moyamoya disease.
The first gene associated with moyamoya disease was RNF213 on chromosome 17.12 
Animal models show that knockout of this gene causes arterial abnormalities with wall 
malformation and abnormal angiogenesis.13 Another study showed that different muta-
tions of this ring finger protein are associated with different clinical presentations of 
moyamoya: R4810K mutation with the ischemic form and A4399T mutation with the 
hemorrhagic form.14 
There is evidence of a dysregulation of a variety of extracellular matrix proteins in 
moyamoya, including basic fibroblast growth factor,15 transforming growth factor beta-
116, and vascular endothelial growth factor.17 A tentative pathologic process is believed 
to be mediated by intimal thickening and 
media attenuation in proximal vessels, 
along with abnormal smooth muscle cell 
turnover and neovascularization in distal 
vessels.18
Moyamoya Syndrome
Moyamoya disease is characterized 
by an idiopathic abnormal vasculature 
adjacent to the circle of Willis with exten-
sive compensatory collateral vessels. 
Moyamoya syndrome is a separate entity, 
associated with another disease that 
causes a similar angiographic appear-
ance.19 The most common examples 
of diseases that can cause moyamoya 
syndrome are sickle-cell disease, neuro-
fibromatosis type I, cranial irradiation, and 
Down syndrome. Even without these risk 
factors, a unilateral presentation is also 
considered to be moyamoya syndrome 
since moyamoya disease is defined as 
a bilateral disease.20 The distinction 
between these two entities is critical for 
an appropriate clinical approach.
CLINICAL PRESENTATION
Moyamoya disease can be asymptom-
atic in early stages, or present with a 
range of symptoms associated with 
the abnormal vasculature including 
headaches, seizures, hemiparesis, and 
sensory impairment. The two major 
types of manifestations are ischemic and 
hemorrhagic. Ischemic symptoms are 
associated with insufficient perfusion and 
infarcts are typically small and located in 
the basal ganglia.21 Hemorrhages can 
occur due to the poorly formed collat-
eral arterial supply and result in a worse 
prognosis.5 Roughly half of patients have 
a single symptomatic episode and half 
have multiple recurrences of ischemic 
events.23 Recurrences in the pediatric 
population are associated with stress, 
hyperventilation, dehydration, and crying, 
which are important factors to recognize 
and explain to the patient’s family for 
prevention measures.19 
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DIAGNOSIS AND IMAGING
It is important that Moyamoya is consid-
ered in patients with stroke-like symptoms 
due to its unique clinical approach. This is 
especially important to keep in mind with 
pediatric patients since 6% of pediatric 
strokes are due to moyamoya disease.5,9,22
Due to the symptoms at presentation, 
the initial imaging study of these patients 
is typically computed tomography (CT). 
CT can identify ischemic lesions from 
the basal ganglia (earlier stages) to the 
cortex (later stages) but can be normal 
if the lesions are small.24 Commonly, the 
diagnosis of moyamoya disease requires 
multiple imaging modalities. Brain MRI is 
more sensitive for these smaller lesions 
and can also identify punctuate flow 
voids in the basal ganglia which is highly 
suggestive of moyamoya disease.19 
The gold standard for diagnosis is conven-
tional cerebral angiography. Transcranial 
Doppler studies can also be useful to 
noninvasively detect stenotic vessels via 
an increased flow rate and track changes 
in this flow over time.25
THERAPEUTIC OPTIONS
The mainstay of treatment for patients of 
all age groups presenting with Moyamoya 
continues to be neurosurgical interven-
tion. Surgery is the only means by which 
the morbidity and mortality of the disease 
can be dramatically reduced. There is 
no agreed upon medical regimen, and 
the only medical options available treat 
the complications of the disease. For 
example; aspirin may be given to inhibit 
the formation of microthromboemboli 
that could cause ischemia (surgical 
patients are given this routinely); calcium 
channel blockers have been reported to 
improve intractable headaches; and fluids 
are given to avoid hypoperfusion.26 
The disease is inevitably progressive,27 
and the single most important prognostic 
indicator is neurologic status at the time 
of treatment.26 Surgery is considered first 
line as a preventative measure against 
stroke and neurologic decline,27 serious 
complications for the relatively young 
patient population affected by moyamoya. 
If there are contraindications to surgery, 
such as a recent stroke or infection, or 
if the patient has adequate collateral 
circulation, medical management may 
be chosen over surgery.27,28 Symptomatic 
patients treated medically show much 
higher rates of recurrent stroke than 
surgical patients.29
Revascularization
Surgical revascularization techniques 
aim to increase cerebral blood flow to 
affected territories, and to indirectly shrink 
the aberrant collaterals that have formed 
as a result of ICA stenosis. A variety of 
direct, indirect and combined surgical 
techniques have been employed, which 
can decrease the frequency of ischemic 
and hemorrhagic events that occur and 
therefore improve functional outcomes.30 
For the purpose of discussion, direct and 
indirect approaches can be separated 
into two distinct categories. In practice, 
however, the combined approach more 
effectively promotes long-term revas-
cularization, and has not been proven 
to increase complication rates over one 
technique alone.23,27
Direct Bypass
Direct revascularization involves the 
anastomosis of the superficial temporal 
artery with the middle cerebral artery, 
distal to the stenotic region.30 This allows 
for an immediate increase in blood flow 
to previously hypoperfused territories 
of the brain. This method has better 
revascularization outcomes than indi-
rect methods alone.23 One concerning 
complication of this method, however, 
if there is inadequate blood pressure 
control, is postoperative hyperperfusion, 
which can lead to seizures.27 Also, this 
bypass is not always feasible in children 
as their vessels are of a smaller diameter,27 
so indirect methods are often relied upon 
in the pediatric population.31
Indirect Revascularization
Indirect revascularization describes a 
number of surgeries with the unifying 
theme of applying richly vascular tissue on 
top of the hypoperfused region in order 
to promote angiogenesis.27 Ultimately, 
the transposed vessel anastomoses 
with the existing vasculature, which can 
significantly improve flow through the 
previously undersupplied vessels. Poten-
tial issues with this technique include 
the time delay of weeks to months 
after surgery before the target tissue is 
perfused, and the potential for mass effect, 
as you are introducing relatively large 
sections of tissue into critically eloquent 
areas of cerebral cortex.32 Tissue can be 
taken from, for example, the omentum 
(omental transplantation) or the tempo-
ralis muscle (encephalomyosynangiosis), 
but the three most commonly utilized 
indirect techniques in North America are 
encephaloduroarteriosynangiosis (EDAS), 
encephaloduroarteriomyosynangiosis 
(EDAMS), and multiple burr hole place-
ment (MBH).30
The EDAS procedure requires suturing the 
STA and a tissue cuff to the dura overlying 
the target area. Burr holes are used to 
facilitate the craniotomy. Many variations 
exist, but one popular technique, pial 
synangiosis, involves attaching the STA 
and tissue cuff directly to the pia. EDAMS 
is a more involved procedure that involves 
utilization of the deep temporal, super-
ficial temporal, and middle meningeal 
arteries.32 MBH is the least invasive tech-
nique, more commonly used in children 
than adults, and requires the placement 
of a number of burr holes through small 
cuts in the periosteum. This allows for 
targeting of specific tissue regions and 
promotes angiogenesis in those areas.32
PROGNOSIS
Moyamoya, as mentioned above, is 
inherently progressive.25,26 The natural 
history of the disease cannot be 
changed by intervention, but it can be 
delayed significantly, and the functional 
status of the patient kept remarkably 
intact.30 Outcomes are best predicted 
by neurologic status at treatment, and 
presentation with a stroke (hemorrhagic 
more than ischemic) was found to be the 
greatest predictor of mortality during 
hospital stay for treatment.5,26,27 In North 
America, where presentation is primarily 
ischemic regardless of age group, child-
hood diagnosis is considered to have a 
worse prognosis.30 When left untreated, 
even asymptomatic patients will progress 
to the point of potentially devastating 
recurrent strokes, but with early diagnosis 
and surgical intervention individuals can 
live for many years with a dramatically 
lower risk of the morbidities associated 
with moyamoya disease.33,34
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CONCLUSION
Moyamoya is a predominantly Asian 
cerebrovascular disease of poorly under-
stood etiology that has seen a global 
increase in incidence in recent decades. 
Moyamoya presents on angiography 
with bilaterally stenosed distal ICAs and 
hazy dilated collateral networks; this 
finding can be idiopathic or present with 
associated diseases such as sickle cell. 
Initial imaging is done using CT or MRI. 
When symptomatic, presentation of isch-
emic or hemorrhagic stroke is the most 
common. The disease is most common 
in young children or middle-aged adults, 
with a female predominance. A variety 
of genetic mutations have been found 
to associate with the disease, but none 
have proven to be causative; there is likely 
interplay between numerous genetic and 
environmental factors.
The disease is inevitably progressive and 
cannot be reversed, but prompt interven-
tion can dramatically reduce the likelihood 
of stroke and neurologic decline. Treat-
ment methods are primarily surgical, with 
a combined method of direct and indi-
rect revascularization showing the best 
results. STA-MCA bypass carries a risk of 
post-operative hyperperfusion, and is not 
feasible in all individuals, such as in chil-
dren with small diameter vessels. Indirect 
revascularization requires months to form 
the necessary anastomoses, and carries 
a risk of mass effect from the introduced 
tissue. While moyamoya is a rare disease 
in the US, the ability to recognize and 
treat affected individuals is essential, 
as devastating stroke can occur if it is 
allowed to progress.
3
Anderson et al.: Moyamoya: A Review of the Disease and Current Treatments
Published by Jefferson Digital Commons, 2014
16 JHN JOURNAL 
31. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, 
Ahn HS: Incidence, prevalence, and survival 
of moyamoya disease in korea: A nationwide, 
population-based study. Stroke 45:1090-
1095, 2014
32. Patel NN, Mangano FT, Klimo P,Jr: Indirect 
revascularization techniques for treating 
moyamoya disease. Neurosurg Clin N Am 
21:553-563, 2010
33. Mukawa M, Nariai T, Matsushima Y, Ohno 
K: Clinical features of familial juvenile cases 
of moyamoya disease: Analysis of patients 
treated in a single institute over a 28-year 
period. J Neurosurg Pediatr 12:175-180, 2013
34. Mukawa M, Nariai T, Matsushima Y, Tanaka Y, 
Inaji M, Maehara T, et al: Long-term follow-
up of surgically treated juvenile patients with 
moyamoya disease. J Neurosurg Pediatr 
10:451-456, 2012
29. Zhao H, You C: Comparison of one-stage 
direct revascularization and medicine therapy 
for treatment of ischemic moyamoya disease. 
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 
23:1097-1100, 2009
30. Arias EJ, Derdeyn CP, Dacey RG,Jr, Zipfel 
GJ: Advances and surgical considerations 
in the treatment of moyamoya disease. 
Neurosurgery 74 Suppl 1:S116-25, 2014
4
JHN Journal, Vol. 9 [2014], Iss. 2, Art. 1
http://jdc.jefferson.edu/jhnj/vol9/iss2/1
